



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

August 2021





© 2021 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2021 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

August 2021

N = 7473



Health Authority	Male	Female	All
FRASER	1475	445	1920
INTERIOR	439	106	545
NORTHERN	136	82	218
VANCOUVER COASTAL	3361	440	3801
VANCOUVER ISLAND	790	167	957
	6201	1240	7441
		Unknown/not stated:	32
		Total:	7473

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown





1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (August 2016 - August 2021)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (August 2016 - August 2021)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (August 2016 - August 2021)






1.5 BC-CfE Enrolment: New Antiretroviral Participants (August 2016 - August 2021)






1.6 Percent Distribution of Active Participants by CD4 Count (August 2016 - August 2021)






1.7 Percent Distribution of Inactive Participants by CD4 Count (August 2016 - August 2021)






1.8 Active and Inactive Participants (August 2016 - August 2021)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (August 2016 - August 2021)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (August 2016 - August 2021)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(August 2016 - August 2021)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (August 2016 - August 2021)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(August 2016 - August 2021)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (August 2016 - August 2021)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(August 2016 - August 2021)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (August 2016 - August 2021)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first ARV Therapy by INGREDIENT

(August 2016 - August 2021)






1.18 Baseline CD4 for Antiretroviral First Starts (August 2016 - August 2021)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (August 2016 - August 2021)






1.20 Cumulative Resistance Testing Results by Resistance Category (August 2016 - August 2021)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (August 2016 - August 2021)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2021
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	29	4	0	4	1	820	4	<40	4
1988	30	5	0	5	3	610	5	<40	3
1989	28	53	1	54	26	455	50	<40	3
1990	27	54	1	55	31	510	53	<40	3
1991	27	38	3	41	24	565	39	<40	3
1992	27	60	5	65	33	610	61	<40	3
1993	26	124	14	138	93	570	135	<40	3
1994	24	75	12	87	54	590	81	<40	3
1995	25	127	18	145	89	540	131	<40	3
1996	23	313	46	359	223	570	334	<40	3
1997	21	269	30	299	203	610	281	<40	3
1998	20	191	43	234	157	590	212	<40	3
1999	20	157	41	198	131	550	177	<40	3
2000	20	119	27	146	99	630	134	<40	3
2001	19	119	27	146	105	590	136	<40	3
2002	18	126	25	151	107	550	139	<40	3
2003	18	142	26	168	108	605	154	<40	3
2004	17	150	40	190	124	580	171	<40	3
2005	16	178	44	222	152	650	207	<40	3
2006	15	167	39	206	139	600	183	<40	3
2007	14	237	51	288	204	626	262	<40	3
2008	13	282	63	345	243	650	318	<40	3
2009	12	300	66	366	246	655	336	<40	3
2010	11	264	68	332	239	660	296	<40	3
2011	10	324	66	390	245	700	337	<40	3
2012	9	279	62	341	236	700	312	<40	3
2013	8	257	61	318	217	680	279	<40	3
2014	7	273	51	324	198	700	277	<40	3
2015	6	271	48	319	221	700	288	<40	3
2016	5	265	52	317	217	693	278	<40	3
2017	4	212	32	244	179	660	231	<40	3
2018	3	189	55	244	170	676	223	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2021
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	2	233	43	276	211	640	262	<40	3
2020	1	192	53	245	182	640	225	<40	3
2021	0	158	31	189	166	560	186	<40	3
Total:		6207	1244	7451					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2020	7358	774	2227	<40	1729	610
FEB-2020	7329	776	1882	<40	1417	620
MAR-2020	7387	768	1628	<40	1207	620
APR-2020	7408	770	767	<40	577	600
MAY-2020	7397	776	1186	<40	892	600
JUN-2020	7368	784	1558	<40	1148	620
JUL-2020	7333	794	1918	<40	1437	610
AUG-2020	7254	791	1848	<40	1332	630
SEP-2020	7233	784	1735	<40	1243	620
OCT-2020	7265	776	1782	<40	1309	630
NOV-2020	7340	763	1858	<40	1284	610
DEC-2020	7347	752	1542	<40	1085	630
JAN-2021	7384	746	1942	<40	1386	630
FEB-2021	7377	748	1787	<40	1272	630
MAR-2021	7432	743	2016	<40	1423	620
APR-2021	7417	746	1828	<40	1318	636
MAY-2021	7453	742	1869	<40	1292	630
JUN-2021	7459	738	1880	<40	1311	610
JUL-2021	7470	743	1822	<40	1286	640
AUG-2021	7473	741	1980	<40	1251	630

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2020	635	185	70	354	46	435
FEB-2020	675	173	71	<40	58	480
MAR-2020	632	188	50	<40	32	415
APR-2020	611	204	28	116	22	555
MAY-2020	630	187	42	<50	30	490
JUN-2020	662	181	56	<40	46	480
JUL-2020	729	161	72	<40	56	625
AUG-2020	819	142	75	<40	65	470
SEP-2020	871	137	93	<40	71	610
OCT-2020	866	178	87	<40	75	570
NOV-2020	794	192	78	<40	63	510
DEC-2020	798	187	65	<40	55	420
JAN-2021	782	203	73	<40	56	525
FEB-2021	795	199	69	<40	56	510
MAR-2021	780	251	89	<40	70	630
APR-2021	813	258	73	<40	58	615
MAY-2021	791	277	72	<40	64	540
JUN-2021	788	272	65	57	47	540
JUL-2021	787	284	51	138	33	530
AUG-2021	800	273	54	<40	39	630

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2020	7328	635	10	12	183	155	18	13903
FEB-2020	7295	675	12	19	141	172	-33	13939
MAR-2020	7358	632	14	23	210	152	63	13975
APR-2020	7382	611	12	8	158	127	24	14000
MAY-2020	7375	630	10	15	130	135	-7	14025
JUN-2020	7345	662	9	9	125	149	-30	14042
JUL-2020	7308	729	15	12	160	189	-37	14074
AUG-2020	7222	819	18	11	168	240	-86	14094
SEP-2020	7193	871	19	9	228	241	-29	14115
OCT-2020	7226	866	20	13	223	176	33	14136
NOV-2020	7310	794	12	12	244	155	84	14162
DEC-2020	7325	798	10	13	205	190	15	14191
JAN-2021	7363	782	14	10	203	159	38	14211
FEB-2021	7355	795	15	14	185	190	-8	14235
MAR-2021	7409	780	15	24	203	156	54	14272
APR-2021	7396	813	13	9	165	172	-13	14297
MAY-2021	7427	791	14	15	177	143	31	14326
JUN-2021	7447	788	6	15	186	173	20	14352
JUL-2021	7455	787	9	13	169	163	8	14373
AUG-2021	7451	800	15	12	170	170	-4	14395

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2020	60	6758	484	56	7358	0.82%	91.85%	6.58%	0.76%	100.00%
FEB-2020	59	6735	477	58	7329	0.81%	91.90%	6.51%	0.79%	100.00%
MAR-2020	60	6790	487	50	7387	0.81%	91.92%	6.59%	0.68%	100.00%
APR-2020	61	6814	483	50	7408	0.82%	91.98%	6.52%	0.67%	100.00%
MAY-2020	60	6806	481	50	7397	0.81%	92.01%	6.50%	0.68%	100.00%
JUN-2020	59	6774	484	51	7368	0.80%	91.94%	6.57%	0.69%	100.00%
JUL-2020	61	6753	471	48	7333	0.83%	92.09%	6.42%	0.65%	100.00%
AUG-2020	70	6676	457	51	7254	0.96%	92.03%	6.30%	0.70%	100.00%
SEP-2020	85	6640	456	52	7233	1.18%	91.80%	6.30%	0.72%	100.00%
OCT-2020	107	6645	462	51	7265	1.47%	91.47%	6.36%	0.70%	100.00%
NOV-2020	162	6673	456	49	7340	2.21%	90.91%	6.21%	0.67%	100.00%
DEC-2020	180	6657	461	49	7347	2.45%	90.61%	6.27%	0.67%	100.00%
JAN-2021	205	6681	452	46	7384	2.78%	90.48%	6.12%	0.62%	100.00%
FEB-2021	226	6652	448	51	7377	3.06%	90.17%	6.07%	0.69%	100.00%
MAR-2021	249	6669	463	51	7432	3.35%	89.73%	6.23%	0.69%	100.00%
APR-2021	275	6644	454	44	7417	3.71%	89.58%	6.12%	0.59%	100.00%
MAY-2021	299	6641	465	48	7453	4.01%	89.11%	6.24%	0.64%	100.00%
JUN-2021	326	6615	472	46	7459	4.37%	88.68%	6.33%	0.62%	100.00%
JUL-2021	354	6599	471	46	7470	4.74%	88.34%	6.31%	0.62%	100.00%
AUG-2021	382	6577	472	42	7473	5.11%	88.01%	6.32%	0.56%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	2 8%	3402 47%	2 8%	3226 45%	0 0%	34 0%	0 0%	1 0%	9 38%	1024 14%	13 54%	2963 41%	22 92%	3763 52%
FEB-2020	3 8%	3351 47%	3 8%	3179 45%	0 0%	33 0%	0 0%	1 0%	16 44%	1169 16%	17 47%	2825 40%	33 92%	3781 53%
MAR-2020	5 14%	3325 46%	5 14%	3160 44%	1 3%	34 0%	0 0%	1 0%	20 56%	1326 18%	11 31%	2719 38%	30 83%	3855 54%
APR-2020	6 24%	3298 46%	5 20%	3137 43%	1 4%	35 0%	0 0%	0 0%	8 32%	1402 19%	11 44%	2637 37%	19 76%	3888 54%
MAY-2020	1 4%	3272 45%	0 0%	3111 43%	0 0%	36 0%	0 0%	0 0%	13 54%	1481 21%	11 46%	2595 36%	23 96%	3914 54%
JUN-2020	5 29%	3242 45%	5 29%	3080 43%	0 0%	33 0%	0 0%	0 0%	4 24%	1585 22%	8 47%	2517 35%	12 71%	3921 55%
JUL-2020	6 19%	3199 45%	4 13%	3039 42%	2 6%	32 0%	0 0%	0 0%	14 44%	1695 24%	12 38%	2420 34%	26 81%	3942 55%
AUG-2020	3 15%	3149 45%	2 10%	2990 42%	0 0%	31 0%	0 0%	0 0%	11 55%	1759 25%	6 30%	2313 33%	17 85%	3913 55%
SEP-2020	3 14%	3121 44%	2 10%	2960 42%	0 0%	31 0%	0 0%	0 0%	13 62%	1868 26%	5 24%	2224 32%	18 86%	3927 56%
OCT-2020	2 10%	3121 44%	2 10%	2944 41%	0 0%	29 0%	0 0%	0 0%	12 57%	1971 28%	7 33%	2135 30%	19 90%	3961 56%
NOV-2020	7 27%	3164 44%	3 12%	2934 41%	1 4%	30 0%	0 0%	0 0%	11 42%	2063 29%	8 31%	2077 29%	19 73%	3990 56%
DEC-2020	3 10%	3151 44%	3 10%	2895 40%	0 0%	29 0%	0 0%	0 0%	14 48%	2144 30%	12 41%	2020 28%	26 90%	4011 56%
JAN-2021	2 10%	3153 44%	1 5%	2880 40%	0 0%	28 0%	0 0%	0 0%	12 60%	2220 31%	6 30%	1962 27%	18 90%	4045 56%
FEB-2021	2 8%	3135 43%	2 8%	2843 39%	0 0%	27 0%	0 0%	0 0%	16 67%	2298 32%	6 25%	1899 26%	22 92%	4061 56%
MAR-2021	8 22%	3140 43%	7 19%	2832 39%	0 0%	24 0%	0 0%	0 0%	23 62%	2368 33%	6 16%	1858 26%	29 78%	4111 57%
APR-2021	2 8%	3137 43%	2 8%	2802 39%	0 0%	25 0%	0 0%	0 0%	17 68%	2422 33%	6 24%	1791 25%	23 92%	4104 57%
MAY-2021	7 24%	3150 43%	3 10%	2784 38%	0 0%	22 0%	0 0%	0 0%	15 52%	2498 34%	10 34%	1759 24%	22 76%	4132 57%
JUN-2021	4 15%	3137 43%	3 12%	2741 38%	0 0%	23 0%	0 0%	0 0%	17 65%	2576 35%	5 19%	1699 23%	22 85%	4156 57%
JUL-2021	3 14%	3126 43%	2 10%	2707 37%	0 0%	23 0%	0 0%	0 0%	14 67%	2631 36%	4 19%	1660 23%	18 86%	4176 57%
AUG-2021	1 5%	3109 43%	1 5%	2667 36%	0 0%	23 0%	0 0%	0 0%	16 73%	2666 36%	5 23%	1633 22%	21 95%	4191 57%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		ritonavir		saquinavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	0 0%	2 0%	0 0%	910 37%	6 86%	1466 59%	1 14%	96 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
FEB-2020	0 0%	2 0%	1 11%	873 36%	8 89%	1454 60%	0 0%	96 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
MAR-2020	0 0%	2 0%	1 10%	860 36%	9 90%	1434 60%	0 0%	93 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
APR-2020	0 0%	2 0%	0 0%	838 36%	4 80%	1412 60%	1 20%	93 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
MAY-2020	0 0%	2 0%	1 10%	834 36%	9 90%	1411 60%	0 0%	89 4%	0 0%	0 0%	0 0%	6 0%	0 0%	0 0%
JUN-2020	0 0%	2 0%	2 33%	812 35%	4 67%	1386 61%	0 0%	86 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
JUL-2020	0 0%	1 0%	0 0%	779 35%	8 100%	1359 61%	0 0%	81 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
AUG-2020	0 0%	1 0%	1 20%	749 35%	4 80%	1327 62%	0 0%	79 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
SEP-2020	0 0%	0 0%	1 33%	734 35%	2 67%	1298 61%	0 0%	79 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
OCT-2020	0 0%	0 0%	0 0%	711 34%	6 100%	1281 62%	0 0%	77 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
NOV-2020	0 0%	1 0%	0 0%	694 34%	3 100%	1270 62%	0 0%	77 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
DEC-2020	0 0%	1 0%	1 8%	677 33%	11 92%	1286 63%	0 0%	76 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
JAN-2021	0 0%	1 0%	0 0%	655 32%	5 100%	1297 64%	0 0%	71 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
FEB-2021	0 0%	1 0%	0 0%	643 33%	5 100%	1262 64%	0 0%	71 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
MAR-2021	0 0%	1 0%	1 25%	621 32%	3 75%	1261 65%	0 0%	73 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
APR-2021	0 0%	1 0%	0 0%	595 31%	4 100%	1230 65%	0 0%	72 4%	0 0%	1 0%	0 0%	2 0%	0 0%	1 0%
MAY-2021	0 0%	1 0%	0 0%	589 31%	4 100%	1239 65%	0 0%	69 4%	0 0%	1 0%	0 0%	1 0%	0 0%	1 0%
JUN-2021	0 0%	1 0%	0 0%	573 31%	4 80%	1222 66%	1 20%	69 4%	0 0%	1 0%	0 0%	1 0%	0 0%	1 0%
JUL-2021	0 0%	1 0%	0 0%	561 30%	6 100%	1218 66%	0 0%	68 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
AUG-2021	0 0%	0 0%	0 0%	548 30%	2 100%	1206 66%	0 0%	65 4%	0 0%	2 0%	0 0%	0 0%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	0 0%	1 0%	3 100%	590 36%	0 0%	202 12%	0 0%	501 31%	0 0%	325 20%
FEB-2020	0 0%	1 0%	4 100%	558 36%	0 0%	198 13%	0 0%	483 31%	0 0%	320 21%
MAR-2020	0 0%	1 0%	4 100%	547 36%	0 0%	195 13%	0 0%	464 31%	0 0%	315 21%
APR-2020	0 0%	1 0%	6 86%	542 36%	0 0%	190 13%	0 0%	456 30%	1 14%	313 21%
MAY-2020	0 0%	1 0%	1 50%	536 36%	0 0%	193 13%	0 0%	452 30%	1 50%	305 21%
JUN-2020	0 0%	1 0%	2 100%	524 36%	0 0%	189 13%	0 0%	447 30%	0 0%	307 21%
JUL-2020	0 0%	3 0%	2 50%	507 35%	0 0%	184 13%	2 50%	438 31%	0 0%	305 21%
AUG-2020	1 100%	4 0%	0 0%	501 36%	0 0%	179 13%	0 0%	421 30%	0 0%	294 21%
SEP-2020	0 0%	5 0%	1 33%	476 35%	0 0%	174 13%	0 0%	409 30%	2 67%	293 22%
OCT-2020	0 0%	9 1%	1 100%	461 35%	0 0%	171 13%	0 0%	402 30%	0 0%	279 21%
NOV-2020	0 0%	10 1%	2 67%	451 35%	0 0%	171 13%	1 33%	393 30%	0 0%	279 21%
DEC-2020	0 0%	11 1%	2 67%	437 34%	0 0%	163 13%	0 0%	383 30%	1 33%	276 22%
JAN-2021	0 0%	11 1%	1 100%	426 34%	0 0%	164 13%	0 0%	379 30%	0 0%	272 22%
FEB-2021	0 0%	15 1%	0 0%	418 34%	0 0%	161 13%	0 0%	365 30%	0 0%	267 22%
MAR-2021	0 0%	21 2%	2 100%	419 34%	0 0%	162 13%	0 0%	365 30%	0 0%	266 22%
APR-2021	0 0%	20 2%	1 50%	409 34%	0 0%	155 13%	1 50%	359 30%	0 0%	260 22%
MAY-2021	1 20%	30 3%	3 60%	397 33%	0 0%	154 13%	0 0%	353 30%	1 20%	259 22%
JUN-2021	0 0%	41 4%	2 100%	379 32%	0 0%	155 13%	0 0%	345 30%	0 0%	252 22%
JUL-2021	0 0%	45 4%	1 100%	372 32%	0 0%	153 13%	0 0%	339 29%	0 0%	246 21%
AUG-2021	0 0%	56 5%	1 100%	366 32%	0 0%	150 13%	0 0%	338 29%	0 0%	244 21%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	9 50%	421 10%	7 39%	2687 62%	0 0%	707 16%	0 0%	32 1%	2 11%	594 14%
FEB-2020	14 52%	602 14%	11 41%	2642 60%	2 7%	654 15%	0 0%	29 1%	0 0%	576 13%
MAR-2020	19 68%	755 17%	7 25%	2623 58%	1 4%	623 14%	1 4%	30 1%	0 0%	562 12%
APR-2020	7 50%	827 18%	6 43%	2589 57%	1 7%	607 13%	0 0%	29 1%	0 0%	544 12%
MAY-2020	10 56%	911 20%	6 33%	2554 56%	2 11%	597 13%	0 0%	27 1%	0 0%	541 12%
JUN-2020	4 31%	1022 22%	9 69%	2537 55%	0 0%	582 13%	1 8%	28 1%	0 0%	538 12%
JUL-2020	9 38%	1140 24%	10 42%	2508 54%	5 21%	549 12%	0 0%	29 1%	0 0%	527 11%
AUG-2020	10 59%	1219 26%	6 35%	2458 52%	1 6%	517 11%	0 0%	29 1%	0 0%	520 11%
SEP-2020	13 87%	1336 28%	2 13%	2440 51%	0 0%	497 10%	0 0%	29 1%	0 0%	504 11%
OCT-2020	10 59%	1444 30%	5 29%	2424 50%	0 0%	493 10%	0 0%	30 1%	2 12%	493 10%
NOV-2020	8 36%	1540 31%	9 41%	2475 50%	2 9%	480 10%	0 0%	27 1%	3 14%	489 10%
DEC-2020	10 53%	1624 33%	7 37%	2465 49%	2 11%	459 9%	0 0%	27 1%	0 0%	477 10%
JAN-2021	12 80%	1697 34%	3 20%	2461 49%	0 0%	442 9%	0 0%	27 1%	0 0%	469 9%
FEB-2021	14 64%	1774 35%	5 23%	2476 49%	3 14%	420 8%	0 0%	24 0%	0 0%	457 9%
MAR-2021	23 72%	1839 35%	9 28%	2491 48%	0 0%	418 8%	0 0%	24 0%	0 0%	454 9%
APR-2021	15 75%	1901 36%	4 20%	2504 48%	1 5%	412 8%	0 0%	22 0%	0 0%	438 8%
MAY-2021	15 65%	1980 37%	7 30%	2509 47%	0 0%	397 7%	0 0%	22 0%	1 4%	439 8%
JUN-2021	16 76%	2058 38%	4 19%	2498 47%	1 5%	387 7%	0 0%	23 0%	0 0%	440 8%
JUL-2021	13 76%	2114 39%	3 18%	2498 46%	1 6%	384 7%	0 0%	23 0%	0 0%	432 8%
AUG-2021	15 71%	2155 40%	5 24%	2487 46%	1 5%	375 7%	0 0%	23 0%	0 0%	425 8%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		IV 3 drugs from 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2020	1617	21.98	1210	16.44	3562	48.41	55	0.75	761	10.34	153	2.08
FEB-2020	1573	21.46	1154	15.75	3643	49.71	55	0.75	757	10.33	147	2.01
MAR-2020	1540	20.85	1134	15.35	3755	50.83	57	0.77	759	10.27	142	1.92
APR-2020	1522	20.55	1129	15.24	3807	51.39	57	0.77	750	10.12	143	1.93
MAY-2020	1512	20.44	1111	15.02	3830	51.78	56	0.76	748	10.11	140	1.89
JUN-2020	1458	19.79	1084	14.71	3881	52.67	55	0.75	752	10.21	138	1.87
JUL-2020	1420	19.36	1058	14.43	3935	53.66	57	0.78	729	9.94	134	1.83
AUG-2020	1375	18.96	1026	14.14	3943	54.36	66	0.91	714	9.84	130	1.79
SEP-2020	1336	18.47	980	13.55	3998	55.27	79	1.09	710	9.82	130	1.80
OCT-2020	1308	18.00	964	13.27	4058	55.86	101	1.39	701	9.65	133	1.83
NOV-2020	1287	17.53	946	12.89	4128	56.24	159	2.17	697	9.50	123	1.68
DEC-2020	1272	17.31	924	12.58	4153	56.53	177	2.41	703	9.57	118	1.61
JAN-2021	1273	17.24	912	12.35	4191	56.76	202	2.74	693	9.39	113	1.53
FEB-2021	1232	16.70	894	12.12	4226	57.29	223	3.02	689	9.34	113	1.53
MAR-2021	1209	16.27	890	11.98	4274	57.51	246	3.31	707	9.51	106	1.43
APR-2021	1166	15.72	868	11.70	4319	58.23	273	3.68	690	9.30	101	1.36
MAY-2021	1146	15.38	858	11.51	4349	58.35	296	3.97	704	9.45	100	1.34
JUN-2021	1125	15.08	835	11.19	4371	58.60	324	4.34	706	9.47	98	1.31
JUL-2021	1106	14.81	824	11.03	4386	58.71	352	4.71	703	9.41	99	1.33
AUG-2021	1091	14.60	819	10.96	4388	58.72	378	5.06	701	9.38	96	1.28

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2020	12	0	2	1	4	4	490
FEB-2020	19	5	1	5	3	5	320
MAR-2020	23	4	0	3	1	10	550
APR-2020	8	0	0	3	0	5	686
MAY-2020	15	1	0	3	4	7	400
JUN-2020	9	1	0	3	4	1	380
JUL-2020	12	3	0	0	2	4	500
AUG-2020	11	3	1	3	2	1	225
SEP-2020	9	3	2	1	0	0	71
OCT-2020	13	2	1	1	3	3	381
NOV-2020	12	0	1	0	2	6	710
DEC-2020	13	3	3	3	0	4	260
JAN-2021	10	1	4	0	1	2	170
FEB-2021	14	0	2	3	4	5	365
MAR-2021	24	4	5	3	5	5	280
APR-2021	9	2	1	1	1	4	370
MAY-2021	15	1	1	3	2	4	480
JUN-2021	15	4	1	3	2	4	289
JUL-2021	13	1	2	1	2	4	445
AUG-2021	12	1	1	4	2	2	300

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2020	12525	4021
FEB-2020	12557	4039
MAR-2020	12558	4030
APR-2020	12536	4006
MAY-2020	12526	3994
JUN-2020	12503	3972
JUL-2020	12480	3939
AUG-2020	12448	3915
SEP-2020	12411	3887
OCT-2020	12389	3875
NOV-2020	12402	3875
DEC-2020	12379	3836
JAN-2021	12388	3838
FEB-2021	12380	3832
MAR-2021	12378	3821
APR-2021	12367	3808
MAY-2021	12362	3796
JUN-2021	12365	3791
JUL-2021	12387	3810
AUG-2021	12382	3816

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved


Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month






3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7473
Aug-2021

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Aug-2021

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant Aug-2021

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant Aug-2021

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant Aug-2021

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant Aug-2021

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	8	8	7
	35-49	10	11	6
	50+	29	41	20
	Total HSDA:	47	60	33
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	74	100	60	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	399	540	303	
THOMPSON/CARIBOO/ SHUSWAP	20-34	19	19	9
	35-49	69	75	49
	50+	117	189	91
	Total HSDA:	205	283	149
Total HA:		725	983	545

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		725	983	545

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	141	194	106
Male	584	789	439

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	545	56	620	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	23	13
	5 years or more	13	10
	<5 years	11	10
	Total HSDA:	47	33
KOOTENAY BOUNDARY	10 years or more	49	38
	5 years or more	15	12
	<5 years	10	10
	Total HSDA:	74	60
OKANAGAN	10 years or more	256	184
	5 years or more	86	71
	<5 years	57	48
	Total HSDA:	399	303
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	126	94
	5 years or more	44	34
	<5 years	35	21
	Total HSDA:	205	149
Total HA:		725	545

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	454	329
	5 years or more	158	127
	<5 years	113	89
Total HA:		725	545

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	51	69	13	28
KOOTENAY BOUNDARY	76	128	24	49
OKANAGAN	230	967	57	291
THOMPSON/CARIBOO/SHUSWAP	141	534	36	130
Total:	498	1698	130	498

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	107

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	6
	20-34	30	32	25
	35-49	99	105	68
	50+	243	334	182
	Total HSDA:	378	477	281
FRASER NORTH	20-34	122	122	79
	35-49	349	373	264
	50+	611	970	474
	Total HSDA:	1082	1465	817
FRASER SOUTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	1016	1344	822
Total HA:		2476	3286	1920

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	10	10	10
	20-34	270	274	190
	35-49	754	819	574
	50+	1442	2183	1146
Total HA:		2476	3286	1920

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	606	772	445
Male	1870	2514	1475

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1920	53	650	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	233	178
	5 years or more	82	55
	<5 years	63	48
	Total HSDA:	378	281
FRASER NORTH	10 years or more	652	468
	5 years or more	243	196
	<5 years	187	153
	Total HSDA:	1082	817
FRASER SOUTH	10 years or more	620	494
	5 years or more	216	171
	<5 years	180	157
	Total HSDA:	1016	822
Total HA:		2476	1920

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1505	1140
	5 years or more	541	422
	<5 years	430	358
Total HA:		2476	1920

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	142	509	30	58
FRASER NORTH	257	1606	48	219
FRASER SOUTH	223	1651	51	494
Total:	622	3766	129	771

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	186
FRASER NORTH	667
FRASER SOUTH	456
Total:	1309

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		352	510
RICHMOND	20-34	34	35	21
	35-49	44	46	35
	50+	112	161	92
	Total HSDA:	190	242	148
VANCOUVER	0-19	9	9	8
	20-34	425	443	278
	35-49	1317	1463	955
	50+	2925	5097	2125
	Total HSDA:	4676	7012	3366
Total HA:		5218	7764	3801

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	11
	20-34	487	506	318
	35-49	1447	1603	1052
	50+	3272	5643	2420
Total HA:		5218	7764	3801

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	607	947	440
Male	4609	6815	3361
Unknown	2	2	0

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3801	55	650	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	206	169
	5 years or more	82	68
	<5 years	64	50
	Total HSDA:	352	287
RICHMOND	10 years or more	112	85
	5 years or more	34	27
	<5 years	44	36
	Total HSDA:	190	148
VANCOUVER	10 years or more	3067	2128
	5 years or more	946	711
	<5 years	663	527
	Total HSDA:	4676	3366
Total HA:		5218	3801

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	3385	2382
5 years or more	1062	806
<5 years	771	613
Total HA:	5218	3801

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	181	409	54	82
RICHMOND	43	295	8	91
VANCOUVER	650	11169	216	5340
Total:	874	11873	278	5513

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	76

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		340	493
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		125	171
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		771	1097
Total HA:		1236	1761	957

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	5
	20-34	120	129	81
	35-49	283	329	227
	50+	827	1297	644
Total HA:		1236	1761	957

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	220	312	167
Male	1016	1449	790

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	957	55	580	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	202	163
	5 years or more	71	51
	<5 years	67	54
	Total HSDA:	340	268
NORTH VANCOUVER ISLAND	10 years or more	82	68
	5 years or more	27	16
	<5 years	16	16
	Total HSDA:	125	100
SOUTH VANCOUVER ISLAND	10 years or more	460	325
	5 years or more	159	134
	<5 years	152	130
	Total HSDA:	771	589
Total HA:		1236	957

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	744	556
	5 years or more	257	201
	<5 years	235	200
Total HA:		1236	957

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries VANCOUVER ISLAND Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	204	902	75	201
NORTH VANCOUVER ISLAND	152	273	47	75
SOUTH VANCOUVER ISLAND	217	1862	40	558
Total:	573	3037	162	834

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	53
NORTH VANCOUVER ISLAND	40
SOUTH VANCOUVER ISLAND	123
Total:	216

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	5	5	*
	35-49	19	22	*
	50+	22	30	*
	Total HSDA:	46	57	26
NORTH WEST	20-34	*	6	0
	35-49	*	39	16
	50+	*	71	37
	Total HSDA:	72	116	53
NORTHERN INTERIOR	0-19	7	7	5
	20-34	23	25	14
	35-49	59	73	43
	50+	104	177	77
	Total HSDA:	193	282	139
Total HA:		311	455	218

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	5
	20-34	32	36	16
	35-49	102	134	72
	50+	170	278	125
Total HA:		311	455	218

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	194	284	136
Female	117	171	82

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	218	52	560	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	26	14
	5 years or more	10	5
	<5 years	10	7
	Total HSDA:	46	26
NORTH WEST	10 years or more	44	31
	5 years or more	18	14
	<5 years	10	8
	Total HSDA:	72	53
NORTHERN INTERIOR	10 years or more	92	68
	5 years or more	64	46
	<5 years	37	25
	Total HSDA:	193	139
Total HA:		311	218

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	162	113
	5 years or more	92	65
	<5 years	57	40
Total HA:		311	218

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	40	62	4	5
NORTH WEST	80	167	16	34
NORTHERN INTERIOR	119	476	19	188
Total:	239	705	39	227

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	7
NORTH WEST	19
NORTHERN INTERIOR	12
Total:	38

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	7	11	6
	KOOTENAY BOUNDARY	7	10	6
	OKANAGAN	27	44	17
	THOMPSON/CARIBOO/SHUSWAP	24	48	17
	Total HA:	65	113	46
FRASER	FRASER EAST	36	48	26
	FRASER NORTH	53	90	42
	FRASER SOUTH	83	117	61
	Total HA:	172	255	129
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	28	51	24
	RICHMOND	8	13	6
	VANCOUVER	479	891	379
	Total HA:	515	955	409
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	49	82	39
	NORTH VANCOUVER ISLAND	16	26	14
	SOUTH VANCOUVER ISLAND	41	85	33
	Total HA:	106	193	86
NORTHERN	NORTH EAST	11	15	8
	NORTH WEST	31	64	25
	NORTHERN INTERIOR	69	110	55
	Total HA:	111	189	88
Total:		969	1705	758

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	611	1095	478
Female	358	610	280

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	758	52	505	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Monthly Report

Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intelence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Monthly Report

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Monthly Report

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

